COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04400838

Andrew Pollard, Prof

Andrew.pollard@paediatrics.ox.ac.uk

2020-05-26

Not recruiting

RCT

Randomized

Sequential assignment

Blind label

multi-center

Prevention

inclusion criteria: - adults aged 18 - 55 years (groups 4, 5, 6 and 11) - adults aged 56-69 years (groups 1, 7, and 9) - adults aged 70 years and older (groups 2, 8, and 10) - able and willing (in the investigator's opinion) to comply with all study requirements. - willing to allow the investigators to discuss the volunteer's medical history with their general practitioner and access all medical records when relevant to study procedures. - for females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination. - agreement to refrain from blood donation during the course of the study. - provide written informed consent. additional inclusion criteria to group 12 (hiv sub-study): - hiv positive - receiving antiretroviral therapy - undetectable hiv viral load - cd4>350 cells/ml

• participation in covid-19 prophylactic drug trials for the duration of the study. note: participation in covid-19 treatment trials is allowed in the event of hospitalisation due to covid-19. the cov002 study team should be informed as soon as possible. • participation in sars-cov-2 serological surveys where participants are informed of their serostatus for the duration of the study. note: disclosure of serostatus post enrolment may accidently unblind participants to group allocation. participation in cov002 can only be allowed if volunteers are kept blinded to their serology results from local/national serological surveys - receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination, with the exception of the licensed seasonal influenza vaccination and the licensed pneumococcal vaccination. participants will be encouraged to receive these vaccinations at least 7 days before or after their study vaccine. - prior or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines). this exclusion criteria will not apply to group 11, as recruitment will be targeted at those volunteers who previously received a chadox1 vectored vaccine. - administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. - any confirmed or suspected immunosuppressive or immunodeficient state (except group 12, where hiv infected participants are allowed); asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days) - history of allergic disease or reactions likely to be exacerbated by any component of chadox1 ncov-19 or menacwy - any history of angioedema. - any history of anaphylaxis. - pregnancy, lactation or willingness/intention to become pregnant during the study. - current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). - history of serious psychiatric condition likely to affect participation in the study. - bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture. - continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban) - suspected or known current alcohol or drug dependency. - any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. - severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed) - history of laboratory confirmed covid-19 (except groups 5d, 5e, 5f, 9, 10 and 11). - seropositivity to sars-cov-2 before enrolment (except groups 5d, 5e, 5f, 9, 10 and 11) - nb: volunteers with previous naat positive results are also allowed in groups 9, 10 and 11 additional exclusion criteria to groups 4, 6, 9 and 10 - history of allergic disease or reactions likely to be exacerbated by paracetamol - note: caution should be taken when recommending paracetamol to adults who already take paracetamol chronically re-vaccination exclusion criteria (two-dose groups only) - anaphylactic reaction following administration of vaccine - pregnancy. an exception to this will be prior to receipt of a booster dose at extra visit b. if a pregnant woman has discussed vaccination with their usual clinician (e.g. gp) and chooses to receive a covid-19 vaccination, this may be administered by the trial team as part of extra visit b. (protocol 19.0) or as part of the provision of treatment to controls. - any ae that in the opinion of the investigator may affect the safety of the participant or the interpretation of the study results

7

University of Oxford

18

100

United Kingdom

Healthy volunteers

N/A

12390

Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.;Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults

None

Phase 2/Phase 3

[{"arm_notes": "5x10^10vp;1", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5x10^10vp prime, 3.5 - 6.5 \u00d7 10^10 vp boost;2;4 weeks apart", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5x10^10vp prime, 2.2x10^10vp boost;2;4-6 weeks apart", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "3.5 - 6.5 \u00d7 10^10 vp;2;4-6 weeks apart", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "0.9 x 10^11 vp/mL, 0,5mL;2;4-6 weeks apart", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "0.9 x 10^11 vp/mL, 0,25mL prime and 0,5mL boost;2;4-6 weeks apart", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1 or 2", "treatment_id": 780, "treatment_name": "Menacwy vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}]